In conclusion, combination therapy of a rexinoid with a retinoid or other nuclear hormone receptor, such as PPARγ, has the potential to decrease tumor growth in poorly differentiated cancers with the appropriate protein targets. This evidence concerns the gene PPARG and cancer.